According to Mallinckrodt Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $1.93 B. In 2022 the company made a revenue of $1.91 B a decrease over the years 2021 revenue that were of $2.20 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $1.93 B | 1.31% |
2022 | $1.91 B | -13.33% |
2021 | $2.20 B | -0.21% |
2020 | $2.21 B | -30.01% |
2019 | $3.16 B | 18.04% |
2018 | $2.67 B | -16.84% |
2017 | $3.22 B | -10.65% |
2016 | $3.60 B | -1.81% |
2015 | $3.67 B | 28.11% |
2014 | $2.86 B | 27.53% |
2013 | $2.24 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 4,696.68% | ๐บ๐ธ USA |
General Electric GE | $67.95 B | 3,403.94% | ๐บ๐ธ USA |
Zogenix ZGNX | $81.69 M | -95.79% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $15.84 B | 717.10% | ๐ฎ๐ฑ Israel |